| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PlGF2 |
| Uniprot No | P49763 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-170 aa |
| 活性数据 | LPAVPPQQWA LSAGNGSSEV EVVPFQEVWG RSYCRALERL VDVVSEYPSE VEHMFSPSCV SLLRCTGCCG DENLHCVPVE TANVTMQLLK IRSGDRPSYV ELTFSQHVRC ECRPLREKMK PERRRPKGRG KRRREKQRPT DCHLCGDAVP RR |
| 分子量 | 17.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人PlGF2蛋白的3篇参考文献示例(注：文献为虚拟示例，实际检索请结合具体数据库)：
1. **文献名称**：*"Efficient Production of Recombinant Human PlGF2 in Escherichia coli: Purification and Functional Characterization"*
**作者**：Smith A, et al.
**摘要**：本研究报道了通过大肠杆菌系统高效表达重组人PlGF2蛋白的优化策略，并通过亲和层析纯化获得高纯度蛋白。功能实验证实其能够激活VEGFR-1受体并促进内皮细胞迁移。
2. **文献名称**：*"PlGF2 Enhances Angiogenesis in Ischemic Tissues via Autocrine VEGF Signaling Pathways"*
**作者**：Zhang Y, et al.
**摘要**：文章探讨了重组人PlGF2蛋白在缺血性疾病模型中的促血管生成作用，发现其通过自分泌VEGF信号通路增强血管内皮细胞增殖和缺血组织修复。
3. **文献名称**：*"Structural and Functional Analysis of PlGF2 Binding to Neuropilin-1 in Tumor Microenvironment"*
**作者**：Lee H, et al.
**摘要**：该研究解析了PlGF2蛋白与Neuropilin-1受体的相互作用结构，并通过体外实验证明重组PlGF2可促进肿瘤微环境中血管通透性和肿瘤细胞侵袭。
如需具体文献，建议在PubMed或Sci-Hub中输入关键词“Recombinant human PlGF2”检索最新论文。
**Background of Recombinant Human PlGF2 Protein**
Placental Growth Factor 2 (PlGF2), a member of the vascular endothelial growth factor (VEGF) family, is a secreted dimeric glycoprotein encoded by the *PLGF* gene. It binds primarily to VEGF receptor-1 (VEGFR-1/Flt-1) and neuropilin co-receptors, modulating angiogenesis, vascular remodeling, and inflammatory responses. Unlike VEGF-A, PlGF2 exhibits specific roles in pathological angiogenesis, particularly in ischemic and inflammatory conditions, while showing minimal activity in normal physiological vessel formation.
Recombinant human PlGF2 is engineered using expression systems (e.g., mammalian or bacterial cells) to produce bioactive forms for research and therapeutic exploration. Its structure typically includes conserved cysteine residues critical for receptor interaction and stability. PlGF2’s unique heparin-binding domain enhances extracellular matrix interactions, influencing cellular migration and tissue repair processes.
In research, recombinant PlGF2 is used to study pregnancy-related vascular adaptations, tumor angiogenesis, and diseases like diabetic retinopathy or atherosclerosis. Preclinical studies highlight its dual role: promoting collateral vessel growth in ischemic tissues while potentially exacerbating pathological angiogenesis in cancers. Therapeutic strategies targeting PlGF2 aim to either inhibit its pro-angiogenic effects in malignancies or harness its regenerative potential in cardiovascular repair. Despite complexities in its signaling crosstalk with other VEGF members, PlGF2 remains a focal point for understanding angiogenic mechanisms and developing targeted therapies.
×
